A randomised, double-blind, placebo-controlled crossover trial of the effects of metformin therapy on vascular and metabolic risk in young women with polycystic ovary syndrome. - Effects of metformin on vascular function in Polycystic Ovary Syndrome

Cardiff University0 个研究点目标入组 36 人开始时间: 2006年7月27日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•1. A diagnosis of polycystic ovary syndrome.
•This will be based on evidence of androgen excess (clinical symptoms of hyperandrogenism and/or elevated testosterone) with ovulatory dysfunction (fewer than 6 menstrual cycles per year), supported by ovarian ultrasound where available. Congenital adrenal hyperplasia, Cushing’s syndrome, androgen-secreting neoplasms, hyperprolactinaemia and thyroid disease will be excluded by biochemical testing.
•2. Patients will be aged between 18 and 30 years.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Pregnancy or the intention to become pregnant during the course of this trial.
•2. Breastfeeding.
•3. A history of current or previous use (within 6 months) of oral contraceptives, antidiabetics or antiandrogens.
•4. Medical history of diabetes or hypertension.
•5. Contraindications to metformin therapy including renal or hepatic impairment.

发起方